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Abstract
The coronavirus pandemic disease 2019 (COVID-19) has changed the face of contemporary medicine. 
However, each and every medical practitioner must be aware of potential early and late complications of 
COVID-19, its impact on chronic diseases — especially ones as common as atrial fibrillation (AF) — 
and the possible interactions between patients’ chronic medications and pharmacotherapy of COVID-19. 
Patients with AF due to comorbidities and, often, elderly age are assumed to be at a higher risk of  
a severe course of COVID-19. This expert consensus summarizes the current knowledge regarding the 
pharmacotherapy of AF patients in the setting of the COVID-19 pandemic. In general, anticoagulation 
principles in quarantined or asymptomatic individuals remain unchanged. Nevertheless, it is advis-
able to switch from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants (NOACs) 
whenever possible due to their consistent benefits and safety with fixed dosing and no monitoring. Ad-
ditionally, in AF patients hospitalized due to mild or moderate COVID-19 pneumonia, we recommend 
continuing NOAC treatment or to switching to low-molecular-weight heparin (LMWH). On the other 
hand, in severely ill patients hospitalized in intensive care units, intravenous or subcutaneous dosing 
is preferable to oral, which is why the treatment of choice is either LMWH or unfractionated heparin. 
Finally, particularly in critical scenarios, the treatment strategy in COVID-19 patients with AF should 
be individualized based on possible interactions between anticoagulants, antiarrhythmics, antivirals, 
and antibiotics. In this consensus, we also discuss how to safely perform COVID-19 vaccination in 
anticoagulated AF patients. (Cardiol J 2021; 28, 5: 758–766)
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The coronavirus pandemic disease (COVID-19) 
has changed the face of contemporary medicine. 
After the initial turmoil in hospitals and paralysis 
of the ambulatory healthcare system in Poland, 
relevant (although not always sufficient) strategies, 
including telemedicine and eHealth solutions in 
ambulatory care, and — in non-specialty hospitals 
— procedures to ensure adequate management 
of medical emergencies and urgencies have been 
implemented. Still, access to both outpatient and 
inpatient care remains markedly restricted and 
aggravated by fear of infection, further discourag-
ing patients from seeking medical assistance. This 
situation needs to be remedied as soon as possible 
to enable appropriate medical care of “chronic” 
patients, preventing them from developing acute 
disease exacerbations, long-term complications, 
or adverse effects from unsupervised treatment. 
Nevertheless, there is a need to be vigilant about 
the possibility of COVID-19 infection in patients 
and acknowledge that this disease will stay with 
us for the next few months or — more probably 
— years. Thus, each and every medical prac-
titioner — irrespective of specialty or place of 
practice (ambulatory care, a specialty hospital, 
non-specialty hospital) — must be aware of poten-
tial early and late complications of COVID-19, its 
impact on chronic diseases, and possible interac-
tions between patients’ chronic medications and 
pharmacotherapy of COVID-19.
Older age and cardiovascular diseases are 
known predictors of a severe course of COVID-19 
[1, 2]. Atrial fibrillation (AF) itself has not been 
identified as an independent risk factor; however, 
AF patients are largely elderly individuals bur-
dened with concomitant diseases, including hy-
pertension, diabetes, heart failure, and/or coronary 
artery disease, which are demonstrably related to 
higher morbidity and mortality in the course of 
severe acute respiratory syndrome coronavirus-2 
(SARS-CoV-2) infection [1, 2]. These patients 
more often require hospitalization for COVID-19 
and antiviral treatment. Furthermore, up to 10% of 
patients with acute respiratory distress syndrome 
develop new-onset AF [3]. Data in SARS-CoV-2 
cases are still scarce, but so far AF was reported 
in 1 in 5 patients hospitalized for COVID-19, with 
higher rates in severe cases [4–6]. Thus, a high 
proportion of patients treated for COVID-19 might 
be receiving medications for AF, which carries 
a high potential for drug interactions.
This expert consensus aims to summarize 
the current knowledge regarding the pharma-
cotherapy of AF patients in the setting of the 
COVID-19 pandemic. Of particular focus herein, on 
optimal anticoagulation in AF patients during the 
COVID-19 pandemic; drug-drug interactions in-
volving anticoagulants, antiarrhythmics, and an-
tivirals for COVID-19 therapy; and COVID-19 
vaccination in anticoagulated AF patients.
Search strategy and expert  
consensus development
A systematic investigation of all published 
literature was conducted to minimize the risk 
of bias. A detailed search of databases (PubMed, 
CENTRAL, Google Scholar and UpToDate) and 
internet resources (websites of the American 
College of Cardiology [https://www.acc.org], 
American Heart Association [https://www.heart.
org], European Society of Cardiology [https://
www.escardio.org], Centers for Disease Con-
trol and Prevention [https://www.cdc.gov], World 
Health Organization [https://www.covid19.who.
int], European Center for Disease Prevention and 
Control [https://www.ecdc.eu], National Insti-
tutes of Health [https://www.covid19guidelines.
nih.gov], Infectious Diseases Society of America 
[https://www.idsociety.org], Polish Association of 
Epidemiologists and Infectiologists [https://www.
pteilchz.org.pl], Agency for Health Technology and 
Tariff System [https://www.aotm.gov.pl], Medscape 
[https://www.medscape.com], and browser Google 
[https://www.google.com]), covering the period 
up to 1st May 2021 was conducted by four in-
dependent investigators (A.T.K., M.K., J.D.K., 
and A.K.C.). Particular attention was paid to 
clinical guidelines, other expert consensus docu-
ments, narrative or systematic reviews, and to 
studies on drug-drug interactions. The follow-
ing keywords were applied: ‘atrial fibrillation’, 
‘coronavirus’, ‘SARS-CoV-2’, ‘anticoagulant’, 
‘anticoagulation’, ‘NOAC’, ‘DOAC’, ‘warfarin’, 
‘drug-drug interaction’, ‘antiarrhythmic’, ‘an-
tiviral’, and ‘vaccine’. References of retrieved 
resources were searched manually for additional 
relevant publications.
Recommendations were made after extensive 
discussion of available scientific evidence by all 
authors. The manuscript was drafted by the first 
three listed authors (A.T.K., M.K., and J.D.K.) and 
the last one (A.K.C.). All authors critically revised, 
corrected, and accepted the manuscript.
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Problems with blood test assessment  
during the COVID-19 pandemic  
in anticoagulated patients
The current pandemic and deliberate home 
isolation restrict mobility and reduce access to 
medical care professionals (both general practi-
tioners and hospitals), as well as services (phar-
macies, laboratories, and nursing care). During 
the COVID-19 pandemic, a substantial number of 
AF patients treated with vitamin K antagonists 
(VKAs) did not have their international normalized 
ratio (INR) assessed to avoid unnecessary contact 
with other people. Based on 2 years of monitoring, 
a 12-week INR follow-up interval (using a detailed 
protocol with titration) extension appears feasible 
for a subset of patients [7]. Therefore, if it is not 
possible to switch to non-vitamin K antagonist 
oral anticoagulant (NOAC) treatment, we suggest 
measuring INR every 6–12 weeks due to logistic 
problems in such patients. Patients with heart 
failure may not be suitable for this intervention [7].
Are there any interactions between  
the SARS-CoV-2 virus and NOACs?
If an AF patient treated with NOACs is infect-
ed with SARS-CoV-2, a healthcare provider should 
consider both the patient’s individual symptoms 
and medical history and then decide whether and 
how the therapy needs to be modified. Until such 
a decision is made, the previous NOAC treatment 
should be continued.
Anticoagulation in non-COVID-19  
patients and in quarantined,  
asymptomatic, or mildly symptomatic 
non-hospitalized individuals
It is advisable to switch away from VKAs to 
NOACs in non-COVID-19 patients with AF when-
ever possible due to their consistent benefits and 
safety with fixed dosing and no monitoring [8]. In 
general, anticoagulation principles in quarantined 
or asymptomatic individuals remain unchanged and 
NOACs are the preferred anticoagulants in the vast 
majority of AF patients (Table 1). Moreover, we 
recommend continuing NOAC therapy in mildly 
symptomatic COVID-19-infected AF patients who 
do not require hospitalization.
Regular kidney function assessments are 
essential for the safety of NOAC therapy. It 
is recommended to use the Cockroft-Gault 
equation for estimation of creatinine clearance 
(CrCl). In NOAC-treated patients without any 
history of kidney dysfunction, CrCl should be 
evaluated at least annually. In case of a clini-
cally relevant decline in CrCl, an adjustment of 
NOAC dose should be considered. In patients 
with CrCl ≤ 60 mL/min, a more frequent assess-
ment of renal function is advised. The minimum 
period between successive kidney function 
assessments in months may be calculated by 
dividing CrCl by 10. In patients with co-existing 
risk factors (e.g., older age, frailty, and multiple 
comorbidities), more frequent monitoring is 
suggested [8–10].
Table 1. Recommendations regarding anticoagulation in atrial fibrillation (AF) patients during the coro-
navirus disease 2019 (COVID-19) pandemic.
1. In non-infected patients, it is advisable to switch from VKAs to NOACs whenever possible due to their  
consistent benefits and safety with fixed dosing and no monitoring.
2. Anticoagulation principles in quarantined or asymptomatic individuals remain unchanged and NOACs  
are the preferred anticoagulants in the vast majority of AF patients.
3. We recommend continuing NOAC therapy in mildly symptomatic COVID-19-infected AF patients who do  
not require hospitalization.
4. We recommend continuing NOAC treatment or switching to therapeutic dosing of LMWH in AF patients  
hospitalized due to mild or moderate COVID-19 pneumonia. When deciding about anticoagulation, potential 
interactions of NOACs with anti-COVID-19 medications and co-morbidities (e.g., impaired renal function) 
should be considered.
5. We recommend anticoagulation with either LMWH or UFH in critically ill COVID-19 patients with AF  
hospitalized in intensive care units.
6. In AF patients treated with VKA and admitted to the hospital due to COVID-19 infection, including those with 
prosthetic heart valves or moderate/severe mitral stenosis, we suggest switching anticoagulation to LMWH  
or UFH.
7. The anticoagulation treatment strategy in COVID-19 patients with AF, particularly in critical scenarios,  
should be individualized based on possible drug-drug interactions.
LMWH — low-molecular-weight heparin; NOAC — non-vitamin K antagonist oral anticoagulant; UFH — unfractionated heparin;  
VKA — vitamin K antagonist
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Optimal anticoagulation in hospitalized 
COVID-19 patients with AF
We recommend continuing NOAC treatment 
or switching to therapeutic dosing of low-mo-
lecular-weight heparin (LMWH) in AF patients 
hospitalized due to mild or moderate COVID-19 
pneumonia. The choice of anticoagulant should be 
individualized. Potential interactions of NOACs 
with anti-COVID-19 medications and co-mor-
bidities (e.g., impaired renal function) should be 
considered. This recommendation is in line with 
opinions of other experts [11].
On the other hand, in severely ill patients 
hospitalized in intensive care units who are fre-
quently intubated and ventilated, intravenous or 
subcutaneous dosing is preferable to oral, which 
is why the treatment of choice is either LMWH or 
unfractionated heparin (UFH) [12–14].
In AF patients treated with VKA and admit-
ted to the hospital due to COVID-19 pneumonia, 
including those with prosthetic heart valves or 
moderate/severe mitral stenosis, we suggest 
switching anticoagulation to LMWH or UFH. This 
recommendation is primarily based on frequent 
interactions between VKAs and drugs used to treat 
COVID-19 infection (Central illustration).
Importantly, acute kidney injury frequently 
occurs in patients hospitalized due to COVID-19 
infection. Its prevalence ranges from 9% to 35% 
of patients, depending on disease severity [15]. 
It should be emphasized that in patients with 
impaired renal function, doses of both NOACs 
and LMWHs should be adjusted or even therapy 
should be stopped, depending on the value of CrCl. 
On the other hand, although intravenous therapy 
with UFH requires activated partial thromboplastin 
time monitoring, it may be safely used regardless 
of kidney function and — in case of bleeding — its 
action may be quickly reversed with protamine 
sulfate. Notably, specific reversal agents for NOACs 
have been developed, i.e., the more widely avail-
able idarucizumab for factor IIa inhibitor (dabi-
gatran) and the less readily available andexanet alfa 
for the factor Xa inhibitors (rivaroxaban, apixaban, 
edoxaban) [16].
According to dabigatran labels, the capsules 
should not be opened — whereas apixaban tablets 
can be crushed and given via gastric tube. However, 
intensive care unit patients may have poor or fluc-
tuating renal function; dabigatran is contraindicated 
in patients with renal function < 30 mL/min, while 
apixaban and rivaroxaban are contraindicated if 
CrCl is < 15 mL/min [8].
COVID-19 patients frequently present with 
markedly elevated concentration of D-dimer. In 
this setting, D-dimer is regarded as a biomarker 
of disease severity and mortality [17, 18]. Optimal 
management strategies in COVID-19 patients with 
high concentrations of D-dimer remain unclear, 
particularly in those with AF and on therapeutic 
anticoagulation.
Current therapy of COVID-19 pneumonia
Treatment of COVID-19 infection has substan-
tially evolved over time. Numerous experimental 
anti-COVID-19 therapies (azithromycin, chloro-
quine, convalescent plasma, hydroxychloroquine, 
interferon beta, lopinavir/ritonavir) have been 
demonstrated to be ineffective. Some of them 
had considerable potential for interactions with 
anticoagulants and antiarrhythmics and were used 
in AF patients.
Contemporary management of mildly symp-
tomatic COVID-19 patients includes rehydration, 
antipyretic and antitussive drugs, and inhaled bude-
sonide [19]. Primary medications recommended for 
moderate or severe COVID-19 pneumonia are rem-
desivir, tocilizumab, dexamethasone, or methyl - 
prednisolone. Additionally, the large majority of 
hospitalized patients require respiratory support 
(i.e., oxygen supplementation through a nasal 
cannula, face mask or venturi mask, high-flow 
oxygen therapy, non-invasive ventilation, me-
chanical ventilation, or extracorporeal membrane 
oxygenation). Antibiotics should be restricted to 
COVID-19 patients with confirmed or suspected 
bacterial co-infection.
Are there any interactions between  
NOACs and antivirals or antibiotics  
used in COVID-19 patients?
Both LMWHs and UFH are free of interactions 
with drugs used in COVID-19 therapy (Central 
illustration). However, they require parenteral 
administration and may cause heparin induced 
thrombocytopenia. On the other hand, multiple 
drug-drugs interactions of VKAs are well known. 
Although numerous potential interactions between 
NOACs and medications used for COVID-19 
therapy were suggested, no detailed information 
has been available so far. Unfortunately, dedi-
cated drug-drug interaction studies are lacking. 
Therefore, we relied on the low-quality evidence 
summarized on the website of The Liverpool Drug 
Interaction Group [20]. 
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P-glycoprotein (P-gp) inhibitors are likely to in-
crease dabigatran concentration and their use may 
expose a patient treated with a standard dabigatran 
dose to the elevated risk of bleeding. Therefore, 
in such patients we recommend careful clinical 
surveillance (aimed at early detection of signs 
and symptoms of bleeding) and/or consideration 
of dabigatran dose reduction. On the other hand, 
P-gp inducers may reduce dabigatran blood con-
centration. As a consequence, potent P-gp inducers 
should not be co-administered with dabigatran.
Importantly, dabigatran is unlikely to exert any 
drug-drug interaction related to the cytochrome 
P450.
No relevant literary citations were identified 
in either MEDLINE or in EMBASE with keywords 
indicating NOACs and antiviral agents used for 
COVID-19 therapy.
No relevant literary citations were identified 
in MEDLINE and EMBASE with terms indicating 
NOACs and antivirals. Particularly, remdesivir has 
no clinically significant drug interactions docu-
mented, likely due to its rapid clearance.
Are there any interactions between  
NOACs and tocilizumab?
The tocilizumab’s summary of product charac-
teristics indicates that tocilizumab interacts with 
cytochrome P450, but any information on drug- 
-drug interaction involving P-gp transport is lacking 













































































































amoxicillin* ≠ ≠ ≠
amoxicillin/clavulanic acid* ≠ ≠ ≠
azithromycin* ≠ ≠ ≠ ≠ ≠ ≠ ≠
cefuroxime* ≠ ≠ ≠
ceftriaxone* ≠ ≠ ≠
dexamethasone ≠ Ø ≠ Ø Ø ≠ Ø ≠
levofloxacin* ≠ ≠ ≠
meropenem* ≠ ≠ ≠
methylprednisolone ≠ Ø ≠ Ø Ø ≠ Ø ≠
piperacillin/tazobactam* ≠ ≠ ≠
remdesivir
tocilizumab Ø Ø Ø Ø Ø Ø Ø Ø
Central illustration. Interactions between anticoagulants, antiplatelets, fibrinolytics and drugs used to treat corona-
virus disease 2019 (COVID-19) patients. Notably, the overall quality of this evidence is very low. This table is based 
on the COVID-19 Drug Interaction website of the University of Liverpool (www.covid19-druginteractions.org). Gray 
color: No information found on the website, but interaction seems unlikely according to the summary of product 
characteristics. Green color: no clinically significant interaction is expected, or potential interaction is likely to be of 
weak intensity, not requiring additional action/monitoring or dose adjustment. Yellow color: Potential weak interaction 
which may require additional monitoring (e.g., more frequent international normalized ratio monitoring if on vitamin K 
antagonist). Orange color: Potential interaction which may require dose adjustment. Red color: The drugs should not 
be co-administered. ≠Potential increased exposure to the anticoagulant, antiplatelet, or fibrinolytic drugs. ØPotential 
decreased exposure to the anticoagulant, antiplatelet, or fibrinolytic drugs. *Antibiotics are only indicated in COVID-19 
patients if bacterial co-infection is present. 
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manufacturers have conducted dedicated studies on 
interactions between the drugs. The dabigatran’s 
label seems to indicate that there is no interaction 
of dabigatran related to the cytochrome P450. Ac-
cording to tocilizumab’s summary of product char-
acteristics, tocilizumab interacts with cytochrome 
P450; no information on drug-drug interaction 
related to P-gp transport was available. According 
to dabigatran’s label, dabigatran is not expected 
to have any cytochrome P450 related drug-drug 
interactions. Tocilizumab may increase warfarin 
metabolism.
Interactions between azithromycin  
and antiarrhythmic drugs
Although the initial enthusiasm towards 
azithromycin as an experimental COVID-19 
therapy has been tempered by neutral results in 
randomized clinical trials [22–24], its use may 
still be considered in patients with concomitant 
bacterial co-infection. Prolonged cardiac repo-
larization and prolonged QT intervals pose a risk 
of developing cardiac arrhythmia and torsades 
de pointes. Azithromycin — as with other mac-
rolides — may lead to an increased risk of ventric-
ular arrhythmias, including torsade de pointes, 
and hence to cardiac arrest. Azithromycin is not 
contraindicated but should be used with caution 
in patients with ongoing proarrhythmic condi-
tions — especially elderly patients and women: 
(1) receiving treatment with other drugs known 
to prolong QT intervals, such as antiarrhythmics 
of class IA (quinidine and procainamide) and 
class III (dofetilide, amiodarone, and sotalol); 
(2) with electrolyte disturbances, particularly 
in patients with hypokalemia or hypomagne-
semia; (3) with significant bradycardia, cardiac 
arrhythmia or severe heart failure. Several ob-
servational studies have shown a rare short- 
-term risk of arrhythmia, myocardial infarction, 
and mortality of cardiovascular causes associated 
with azithromycin. These findings should be 
taken into account and balanced against the clini-
cal benefits when administering azithromycin.
Antiarrhythmic drugs used  
in the rhythm control strategy
An integral part of AF treatment is restoring 
sinus rhythm. Rhythm control therapy is often 
necessary to improve symptoms in AF patients 
who are symptomatic on rate control therapy. 
Importantly, the underlying hypoxemia, inflam-
mation, and dyselectrolytemia (i.e., hypokalemia, 
hypomagnesemia, and acidosis) may be triggers 
for AF in patients with COVID-19 infection [11]. 
They should be corrected if possible and then if 
AF persists, therapy with antiarrhythmics may be 
considered. In the setting of COVID-19 infection, 
chemical cardioversion is preferred over its electri-
cal counterpart as the first choice AF management in 
hemodynamically stable patients [31]. Amiodarone 
is a known substrate for both CYP3A4 and CYP2C8. 
The concomitant use of drugs inhibiting these iso-
enzymes may inhibit amiodarone metabolism and 
increase its concentration and exposure [25–28]. 
The document of product characteristics recom-
mends to avoid or to pay extreme caution with 
the concomitant use of amiodarone with CYP3A4 
inhibitors. Interactions between amiodarone and 
inhibitors of CYP3A4 may be observed for several 
months after discontinuation of such treatment due 
to the long half-life of amiodarone.
Propafenone is known to be metabolized by 
CYP2D6, CYP3A4, and CYP1A2 enzymes. The 
concomitant use of drugs inhibiting these iso-
enzymes leads to increased plasma levels of 
propafenone [28, 29]. Patients should be care-
fully monitored and the dose adjusted accord-
ingly when propafenone is used with inhibitors 
of these enzymes. The summary of product 
characteristics warns against the simultaneous 
use of propafenone with CYP2D6 and CYP3A4 in-
hibitors. Moreover, co-administration of CYP3A4 
inhibitors may increase exposure to propafenone 
and the risk of QRS complex prolongation on 
electrocardiography, dangerous complex ventricu-
lar arrhythmias, and blockage of beta-blockers. 
Adequate caution is necessary if these drugs are 
used together. Low-doses of propafenone may be 
considered in selected patients diagnosed with 
COVID-19 if the electrocardiography is carefully 
monitored for the early recognition of acquired 
QTc prolongation, torsade de pointes, and other 
dangerous ventricular arrhythmias.
In summary, antiarrhythmics have mild inter-
actions with tocilizumab, moderate interactions 
with steroids, and moderate or severe interactions 
with antibiotics (Fig. 1). On the other hand, no in-
teractions between antiarrhythmics and remdesivir 
were reported.
Antiarrhythmic drugs used  
in the rate control strategy
Both verapamil and diltiazem have been shown 
to be inhibitors of CYP3A4 enzymes and P-gp. 
www.cardiologyjournal.org 763
Anna Tomaszuk-Kazberuk et al., Atrial fibrillation in the era of COVID-19
Simultaneous use of CYP3A4 inhibitors leads 
to elevations of their plasma levels. Doses of 
verapamil and diltiazem should potentially be 
decreased. Beta-blockers such as metoprolol, 
carvedilol, and propranolol are substrates for the 
cytochrome CYP2D6 enzyme [30]. Metoprolol is 
highly dependent on the CYP2D6 enzyme, with 
about 70–80% of its metabolism being through this 
pathway. The other beta-blockers are much less 
reliant on CYP2D6 than metoprolol. The metabo-
lism of digoxin is not dependent on cytochrome 
P450; its elimination is mainly through the kid-
neys and involves P-gp [31]. It is also advisable to 
reduce the dose of digoxin and to continue moni-
toring. No dosage reduction is indicated in the 
case of concomitant administration of tocilizumab 
used in patients with COVID-19 [28].
Based on previous clinical experience and 
the risk of drug-drug interactions, beta-blockers 
are recommended as a first-line therapy for rate 
control strategy [32].
COVID-19 vaccination in patients  
receiving anticoagulants
Public Health England’s Immunization Against 
Infectious Disease states that the vaccine may be 
given intramuscular to patients treated with warfa-
rin whose latest INR is lower than the upper limit 
of the therapeutic range [32].
For the vaccination a thin needle should be 
used and then firm pressure applied to the site 
of injection for at least 2 min. The information of 
possible hematoma from the injection should be 
conveyed to the patient. If the level of anticoagula-
tion is unknown, the general practitioner or doctor 
in charge responsible for anticoagulant treatment 
should be contacted. 
COVID-19 vaccine may be also given to pa-
tients who are treated with NOACs. The 2021 
Update of European Heart Rhythm Association 
Consensus on NOACs recommends: (1) to skip the 
morning dose of the NOAC before intramuscular 




azithromycin* ! ≠ !
cefuroxime*
ceftriaxone*
dexamethasone Ø # ^ # # #
levofloxacin* ! ≠
meropenem* ≠




Figure 1. Interactions between antiarrhythmics and drugs used to treat coronavirus disease 2019 (COVID-19) pa-
tients. Notably, the overall quality of this evidence is very low. This table is based on the COVID-19 Drug Interaction 
website of the University of Liverpool (www.covid19-druginteractions.org). Gray color: No information was found 
on the website, but interaction seems unlikely according to the summary of product characteristics. Green color: no 
clinically significant interaction is expected, or potential interaction is likely to be of weak intensity, not requiring ad-
ditional action/monitoring or dose adjustment. Yellow color: Potential weak interaction which may require additional 
monitoring. Orange color: Potential interaction which may require dose adjustment. Red color: The drugs should 
not be co-administered. ≠Potential increased exposure to the antiarrhythmic drug. ØPotential decreased exposure 
to the antiarrhythmic drug. *Antibiotics are only indicated in COVID-19 patients if bacterial co-infection is present. 
! Both drugs (when co-administered) may lead to marked QT interval prolongation and increase the risk of torsades 
de pointes. #Steroids may cause hypokalemia, which increases the risk of torsades de pointes with antiarrhythmics. 
^Steroids may cause hypokalemia, which increases the risk of digoxin toxicity. 
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injection, (2) in NOACs taken twice daily, to take 
the morning dose 3 h after the vaccination espe-
cially in high risk of ischemic stroke, and (3) in 
NOACs taken twice a day, start NOAC with the 
next regular dose [8]. The rules concerning reduc-
tion the risks of hematoma after vaccination are the 
same as described for warfarin above.
Summary
Patients with AF due to comorbidities and 
elderly age are assumed to be at a higher risk of 
a severe course of COVID-19. In general, anticoagu-
lation principles in quarantined or asymptomatic 
individuals remain unchanged. It is advisable to 
switch from VKAs to NOACs whenever possible 
due to their consistent benefits and safety with 
fixed dosing and no monitoring. Additionally, in 
AF patients hospitalized due to mild or moderate 
COVID-19 pneumonia, we recommend continuing 
NOAC treatment or switching to LMWH. On the 
other hand, in severely ill patients hospitalized in 
intensive care units, intravenous or subcutaneous 
dosing is preferable to oral, which is why the treat-
ment of choice is either LMWH or UFH. Finally, 
particularly in critical scenarios, the treatment 
strategy in COVID-19 patients with AF should 
be individualized based on possible interactions 
between anticoagulants, antiarrhythmics, antivi-
rals, and antibiotics. COVID-19 vaccination may 
be safely performed in anticoagulated AF patients.
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